Table 7.
Safety lab values.
| Baseline | 12 weeks | Difference | Significance | ||
|---|---|---|---|---|---|
| Albumin | Active | 4.4 ± 0.2 | 4.2 ± 0.30 | −0.20 | P = 0.351 |
| Placebo | 4.29 ± 0.018 | 4.3 ± 0.05 | 0.01 | ||
| AST | Active | 22.33 ± 5.55 | 20.92 ± 4.41 | −1.40 | P = 0.406 |
| Placebo | 22.64 ± 8.61 | 21.71 ± 6.10 | −0.90 | ||
| ALT | Active | 21.87 ± 9.26 | 22.31 ± 9.97 | 0.44 | P = 0.243 |
| Placebo | 22.29 ± 12.57 | 23.71 ± 8.71 | 1.42 | ||
| Alkaline phosphatase | Active | 77.73 ± 19.19 | 68.85 ± 19.0 | −8.90 | P = 0.573 |
| Placebo | 75.00 ± 15.85 | 70.43 ± 19.84 | −4.60 | ||
| Total bilirubin | Active | 0.78 ± 0.44 | 0.78 ± 0.63 | 0.00 | P = 0.271 |
| Placebo | 0.73 ± 0.18 | 0.66 ± 0.24 | −0.10 | ||
| BUN | Active | 16.33 ± 4.82 | 17.23 ± 3.63 | 0.90 | P = 0.668 |
| Placebo | 16.86 ± 4.74 | 17.57 ± 5.37 | 0.71 | ||
| Creatinine | Active | 1.08 ± 0.13 | 1.08 ± 0.13 | 0.00 | P = 0.267 |
| Placebo | 1.09 ± 0.16 | 1.05 ± 0.23 | −0.00 | ||
| Estimated GFR | Active | 77.0 ± 11.7 | 78.08 ± 10.3 | 1.08 | P = 0.296 |
| Placebo | 77.21 ± 15.2 | 82.21 ± 20.2 | 5.00 |